Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemalenograstim alfa for prevention of chemotherapy-induced neutropenia in CRC/Pancreatic Cancer
NCT06134765Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of efbemalenograstim alfa in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: The incidence of reduced absolute neutrophil count (ANC) of grade >=3 in the first cycle of chemotherapy at Cycle 1. Status: unknown.
02
Drugs
efbemalenograstim alfa
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT06134765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134765.